AbbVie's Humira shines in skin disease with no competitors
This article was originally published in Scrip
Executive Summary
AbbVie's Humira (adalimumab) reduced lesions associated with hidradenitis suppurativa (HS) – a chronic skin disease with no approved treatments and no other therapies in development – in the Phase III placebo-controlled PIONEER I clinical trial.